Abstract
Cancer research is rapidly evolving with the proliferation of molecular targeted therapies. New types of adaptive, basket, and umbrella trials came to fore to assess innovative treatments tied to the existence of selected biomarkers rather than histological site. There is a lack of sound methodological guidance on conducting health economic evaluations alongside new trial designs. This study aims to investigate 1) how clinical evidence from such trials can be used in economic analyses, and 2) how HTA can respond to the paradigm shift in cancer research and development.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
